Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: Curis is a drug discovery and development company focused on leveraging signaling pathway technologies to create new medicines, primarily for cancer. The company operates in a single segment: the research and development of innovative cancer therapeutics. It relies on strategic collaborations (notably with Genentech) and internal development programs to advance its pipeline.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Total Revenues | $2,067,583 | $2,362,786 |
| Net Loss | $(3,430,667) | $(3,540,773) |
| Loss Per Share (Basic & Diluted) | $(0.05) | $(0.07) |
| Operating Cash Flow | $(5,976,750) | $(3,623,701) |
| Cash and Cash Equivalents (End of Period) | $16,241,439 | $16,498,533 |
| Marketable Securities | $18,990,208 | $24,062,577 |
| Total Current Assets | $35,868,279 | $42,039,096 |
| Total Current Liabilities | $2,866,116 | $6,629,372 |
| Debt (Current Portion) | $93,483 | $403,832 |
| Accumulated Deficit | $(699,278,405) | $(695,847,738) |
Material Changes vs. Prior Period
- Revenue Composition: Total revenue decreased by approximately 12% ($295,000). This was driven by a significant 83% drop in "Research and development contracts" ($1.07M decrease) as funding from collaborators (Genentech and Wyeth) concluded. This decline was partially offset by a 72% increase in "License fees" ($773,000 increase), primarily due to the recognition of $1.75 million in revenue from the sale of BMP assets to Stryker Corporation.
- Operating Expenses:
- R&D Expenses: Increased 5% to $3.48M. The increase was driven by $1.72M in spending on the internal lead candidate CUDC-101, offset by reduced spending on collaborator-funded programs.
- G&A Expenses: Decreased 18% to $2.42M, largely due to a $390,000 reduction in legal services costs related to foreign patent applications.
- Liquidity: Cash and cash equivalents decreased by $1.16M during the quarter. Net cash used in operating activities increased to $5.98M (from $3.62M in Q1 2007), primarily due to the net loss and a decrease in deferred revenue as the Stryker license fee was recognized.
- Debt: Current debt decreased significantly as the company made final repayments on its notes with Boston Private Bank & Trust Company on April 1, 2008.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Capital Resources: Management anticipates that existing capital resources ($35.2M in cash and marketable securities) will fund operations into the fourth quarter of 2009.
- Development Pipeline:
- Genentech Collaboration: Genentech is conducting Phase I trials for GDC-0449 (Hedgehog antagonist). Genentech plans to initiate Phase II trials in advanced basal cell carcinoma, metastatic colorectal cancer, and an undisclosed solid tumor in the second half of 2008. A $3.0M contingent payment is due upon the initiation of the colorectal cancer trial.
- Internal Programs: Curis is advancing CUDC-101 (a multi-targeted inhibitor) toward an Investigational New Drug (IND) application filing, expected in mid-2008. The company also plans to select a second development candidate from its Hsp90 inhibitor class in 2008.
- Collaboration Status: The collaboration with Wyeth regarding Hedgehog agonists is set to terminate on May 6, 2008. Curis intends to seek new licensing opportunities for this technology.
Risks and Contingencies
- Need for Financing: The company has never been profitable and expects to incur substantial losses. Future funding depends on collaborations, equity/debt financing, or milestone payments, which are not assured.
- Collaborator Dependence: Success is heavily dependent on Genentech's progress with GDC-0449. Genentech has discretion over resource allocation and may terminate the agreement.
- Regulatory and Clinical Risks: All product candidates are in early stages. Clinical trials may fail, be delayed, or result in regulatory rejection.
- Stock Price Volatility: The company faces risks related to maintaining NASDAQ listing requirements (minimum bid price of $1.00) and potential dilution from future equity offerings.
Key Facts for Investor Verification
- Runway: Verify if the projected cash runway into Q4 2009 remains accurate given the current burn rate and lack of new research funding revenue.
- Genentech Milestones: Monitor the initiation of Phase II trials for GDC-0449 in the second half of 2008, which would trigger a $3.0M payment to Curis.
- Wyeth Termination: Confirm the status of the Wyeth collaboration termination (May 6, 2008) and any subsequent licensing deals for the Hedgehog agonist technology.
- Internal IND Filing: Track the progress of the IND application for CUDC-101, expected in mid-2008, as a critical milestone for internal development.
- Debt Status: Confirm that all debt obligations with Boston Private Bank & Trust Company have been fully satisfied as of April 1, 2008.